Philadelphia, PA, United States
Philadelphia, PA, United States
SEARCH FILTERS
Time filter
Source Type

The new task order, including all options, has a maximum value of $38 million over a five-year period. CDI will be the principal contractor to CNSP providing subject matter experts to conduct Sailor-centric engineering and combat systems training, material review, program auditing, and naval readiness support to enhance overall proficiency and material readiness. The goal is to enhance CNSP ships' readiness to conduct sustained operations at sea in support of the nation's strategic objectives. "The Readiness Assistance Team prime contract is an important opportunity for CDI to provide service and support to our nation's warfighters," said Joseph Barbano, President of CDI Government Services. "We are extremely proud of the Navy's confidence in CDI as a prime contractor, as expressed by this important new support contract to the Fleet. Our Readiness Assistance Team members are excited to be working side-by-side with Fleet Sailors performing this vital service." CDI Corp. (NYSE: CDI) seeks to create extraordinary outcomes with our clients by delivering solutions based on highly skilled and professional talent. Our business is comprised of four segments: Enterprise Talent, Specialty Talent & Technology Solutions, Engineering Solutions and MRI. Our client offerings include an array of engineering design project solutions, information technology project solutions and managed services, specialty technology staff augmentation, and program and managed staffing services. Our clients are corporations in multiple industries, including energy, chemicals, infrastructure, aerospace, industrial equipment, technology, as well as municipal and state governments, and the U.S. Department of Defense. We have offices and delivery centers in the United States and Canada. In addition, we also provide recruiting and staffing services through our global MRINetwork® of franchisees. Learn more at www.cdicorp.com. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements that address expectations or projections about the future, including, but not limited to, statements about our revenue from contracts, are forward-looking statements. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions that are difficult to predict. Because these forward-looking statements are based on estimates and assumptions that are subject to significant business, economic and competitive uncertainties, many of which are beyond our control or are subject to change, actual outcomes and results may differ materially from what is expressed or forecasted in these forward-looking statements. Important factors that could cause actual results to differ materially from these forward-looking statements include, but are not limited to: levels and timing of spending by our clients; our performance under our contracts with clients; and our level of success in attracting, training, and retaining qualified employees. More detailed information about these and other risks and uncertainties may be found in our filings with the United States Securities and Exchange Commission (SEC), particularly in the "Risk Factors" section in Part I, Item 1A of the Company's Annual Report on Form 10-K for the year ended December 31, 2016. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We assume no obligation to update such statements, whether as a result of new information, future events or otherwise, except as required by law.


CAMBRIDGE, Mass.--(BUSINESS WIRE)--Crestovo, a clinical-stage biopharmaceutical company developing Full-Spectrum Microbiota™ (FSM™) that harnesses the human gut microbiome, today announced that patients have been enrolling since the beginning of June in the company’s PRISM 3 clinical trial, evaluating its lead product candidate, CP101, for the prevention of recurrent Clostridium difficile infection (CDI). “We are pleased to have dosed patients in the PRISM 3 trial with CP101 as the leading candidate from our Full-Spectrum MicrobiotaTM platform. CP101 has the potential to be the first therapy seeking FDA-approval utilizing the human gut microbiome,” said Joseph Lobacki, Crestovo’s chief operating officer and interim chief executive officer. PRISM 3 builds on the clinical success of Crestovo’s academic collaborators, Dr. Alexander Khoruts and Dr. Michael Sadowsky, who developed a leading early-stage oral formulation of a microbiota-based product in 2014. As published in The American Journal of Gastroenterology, Dr. Khoruts’ clinical team administered their product to 49 patients with recurrent CDI. Overall, 88% of patients achieved a clinical success, defined as no recurrence of CDI over two months. Additionally, sequence analysis of the fecal microbiome demonstrated near normalization of the fecal microbial community one month following treatment. “The PRISM 3 trial represents a major milestone towards bringing a restorative, full-spectrum, orally-administered microbiome therapy to the many patients with dysbiosis-related diseases in need,” said Dr. Khoruts. “There is a critical, unmet medical need for new treatments for recurrent CDI in the U.S., with antibiotics often further exacerbating the problem of dysbiosis in such patients,” said Dr. Thomas Borody, a scientific founder of Crestovo. “Unlike other therapies in development across the industry, CP101 combines the ease of oral administration with the potential clinical benefits of a Full-Spectrum Microbiota™ composition. We are excited to further the work of Dr. Khoruts and Dr. Sadowsky in restoring proper ecological diversity to patients’ microbiomes to break the cycle of CDI recurrence.” PRISM 3 is a multicenter, randomized, placebo-controlled trial to evaluate the efficacy and safety of CP101 in approximately 240 patients with recurrent CDI at clinical sites throughout the U.S. The primary endpoint of PRISM 3 is prevention of recurrence of CDI through eight weeks following administration of CP101, compared to placebo. Prevention of recurrence of CDI is defined as absence of symptomatic, laboratory confirmed CDI. The trial is actively enrolling patients, and Crestovo expects to report top-line data in 2018. About CP101 CP101 is Crestovo’s potential first-in-class, lead microbiome therapy generated from the company’s Full-Spectrum MicrobiotaTM (FSMTM) platform. As an encapsulated, orally-administered FSMTM therapy, CP101 contains the full complement of functional microorganisms that may help restore the dysbiotic microbiota (or microbial imbalance) to a normal, functioning gut microbial community. Beyond CP101, Crestovo is developing a pipeline of FSM™ therapeutics to treat a range of serious diseases. About Dr. Thomas J. Borody Dr. Borody is a world-renowned leader in the clinical microbiota dating back to 1988 when he started performing what is now called Fecal Microbiota Transplantation (FMT). As a practicing clinician leading the Centre for Digestive Diseases in Australia, he has overseen over 12,000 FMTs, creating a wealth of proprietary clinical data and insights. In addition, Dr. Borody has established novel therapies in the gastrointestinal field, including areas such as Inflammatory Bowel Disease, Irritable Bowel Syndrome, CDI, Parasite infestation, and Resistant Helicobacter pylori via a bismuth-based ‘Triple Therapy’. His knowledge and expertise are sought after by patients from around the world, and he is a reviewer for leading medical journals such as Clinical Journal of Gastroenterology, the Medical Journal of Australia, the American Journal of Gastroenterology and Digestive Diseases and Sciences, among others. He is a scientific founder of Crestovo and serves as an active scientific advisor to the company. About Dr. Alexander Khoruts and Dr. Michael Sadowsky Dr. Khoruts, a prominent gastroenterologist and immunologist, partnered with Dr. Sadowsky, a microbiologist and microbial ecologist, to develop the foundational protocols of standardizing fecal microbiota preparation and preservation. They were the first to demonstrate sustained engraftment of donor bacteria into a patient suffering from recurrent CDI, a finding that led to coining the treatment as ‘Fecal Microbiota Transplantation’ (FMT). The team has continued their focus on mechanistic investigations of FMT and developing next-generation microbiota products that can be used in treatment of CDI and for other clinical indications. They both are key academic collaborators with the Crestovo team. About Clostridium difficile infection (CDI) CDI is a bacterial infection causing patients to suffer from diarrhea, fever, nausea and abdominal pain. The Centers for Disease Control (CDC) has named it an urgent public health threat and the leading hospital-acquired infection in the U.S., with more than 700,000 patients infected annually and 29,000 deaths per year. CDI is estimated to cause approximately $4.8 billion in excess health care costs for acute care facilities alone, given the high number of hospitalizations to treat the disease. Historically, standard-of-care antibiotic treatment presents a risk of recurrence in approximately 60 percent of patients who have experienced multiple recurrences, highlighting a clear unmet medical need. About Crestovo Crestovo is a clinical-stage biopharmaceutical company developing Full-Spectrum Microbiota™ (FSM™) that harnesses the human gut microbiome. Crestovo is advancing the foundational clinical research of the company’s academic collaborators, Dr. Thomas Borody, Dr. Alexander Khoruts and Dr. Michael Sadowsky, which demonstrated in-human validation of an orally-available, microbiota-based product across a variety of serious diseases and unmet medical needs, including recurrent Clostridium difficile infection (CDI). Crestovo’s lead FSM™ product, CP101, is currently being evaluated in the PRISM 3 clinical trial in patients with recurrent CDI. For more information, please visit www.crestovo.com.


"We're excited to launch the next generation of HuProt at ASCO 2017 in Chicago on June 3. With each version - and this is v3.1 - we are adding new proteins with the ultimate goal of having the entire human proteome on a slide." said Scott Paschke, CDI VP of Marketing. "Further, the proteins added to the latest generation represent finer coverage of proteins involved in autoimmune-related toxicities and conditions, transcription factor binding, and signal transduction pathways." In mid-2016, CDI purchased an Arrayjet Ultra Marathon II non-contact piezoelectric (ink jet) robotic printer for its microarray manufacture. This high-capacity state-of-the-art instrument offers significant performance advantages over contact print methods including significant reductions in lot-to-lot variability and inter-assay variability. *HuProt microarrays are available for purchase by labs with in-house microarray scanning capability. Alternatively, CDI's Discovery Services division offers contract assay design, research, bioinformatics and custom-configured microarray production on a per-project basis. About CDI - A privately-owned biotechnology corporation, CDI focuses on protein- and antibody microarray design, production and custom assay services. CDI's flagship - HuProt™ - is the most comprehensive human proteome microarray in the industry, allowing thousands of protein interactions to be done in parallel. HuProt enables R&D of future therapeutic and diagnostic tools to proceed more rapidly and cost-effectively. CDI's Fast-MAb® hybridoma development service addresses the urgent need for monoclonal antibodies with unprecedented specificity for research, diagnostic or therapeutic targets. Fast-MAb antibodies are evaluated for specificity on the HuProt array. The Company exports products world-wide and is expanding its clientele base and its academic and industrial collaborations. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cdi-labs-expands-huprot---the-highest-content-human-proteome-microarray-in-the-world-300463306.html


Patent
Cdi Inc. | Date: 2016-10-18

A flowmeter of the target type, having a flow-sensing probe constructed to be inserted into a pipe through a small hole. The required small size is achieved in part by allowing the probe to deflect and thus shift in orientation relative to the flow as the force on the probe changes, the resulting distortion of the signal being compensated for in firmware. The target is made contiguous with its support, maximizing the area presented to the flow relative to the size of the hole through which the probe is inserted. The flowmeter may be configured to be mounted to the outside of a pipe and include means for sealing to the outside of the pipe. It may also include pressure- and temperature-sensing elements and means to calculate mass flow of a gas.


News Article | May 10, 2017
Site: www.prnewswire.com

Summary Results from Operations for the First Quarter 2017 For the first quarter 2017, revenue of $187.6 million compares to prior-year first quarter revenue of $210.6 million, adjusting for the sale of Anders. Enterprise Talent revenue of $102.2 million compares to prior-year first quarter revenue of $139.6 million, or $116.7 million excluding Anders. Specialty Talent & Technology Solutions revenue of $17.9 million compares to prior-year first quarter revenue of $18.4 million.  Specialty Talent revenue of $10.2 million compares to prior-year first quarter revenue of $10.0 million, while Technology Solutions revenue of $7.7 million compares to prior-year first quarter revenue of $8.4 million. 1 Adjusted EBITDA excludes from net loss interest, income taxes, depreciation and amortization expense, restructuring and other related costs, share-based compensation expense, certain corporate development related items and earnout adjustments. See the financial tables accompanying this release for more information on non-GAAP financial measures and the reconciliation of these measures to GAAP measures. Engineering Solutions revenue of $56.2 million compares to prior-year first quarter revenue of $63.3 million.  Energy, Chemicals and Infrastructure (EC&I) revenue of $27.4 million compares to prior-year first quarter revenue of $34.0 million.  Aerospace and Industrial Equipment (AIE) revenue of $12.6 million compares to prior-year first quarter revenue of $13.1 million.  Government Services revenue of $16.2 million was flat with the prior-year first quarter. Management Recruiters International, Inc. (MRI) revenue of $11.3 million compares to prior-year first quarter revenue of $12.2 million.  Contract Staffing revenue of $8.9 million compares to prior-year first quarter revenue of $9.2 million, while Royalty & Franchise Fees of $2.4 million compare to the prior-year figure of $3.0 million. Gross profit of $34.1 million compares to prior-year first quarter gross profit of $43.3 million, or $39.4 million when excluding Anders, a decline of $5.3 million.  Gross margin when excluding Anders declined 50 basis points year-over-year, to 18.2%. The Company reported an operating loss in the first quarter of $5.9 million compared to an operating loss of $3.8 million in the year-ago quarter. Operating and administrative expenses in the first quarter were $40.0 million versus prior-year first quarter of $47.0 million, or $42.7 million when excluding Anders, an improvement of $2.7 million. More detailed segment data are included in the tables accompanying this release and in the Company's Form 10-Q Report. CDI ended the first quarter with $6.7 million in cash and cash equivalents versus $3.2 million at the end of 2016 and $9.8 million as of March 31, 2016. The Company had $14.2 million of debt outstanding as of March 31, 2017, versus no debt outstanding at December 31, 2016, and $16.9 million outstanding as of March 31, 2016. Cash flow from operating activities was a deficit of $7.9 million in the first quarter of 2017 versus a deficit of $0.7 million in the first quarter of 2016. Liquidity, including availability under CDI's bank and credit facilities, totaled $117.0 million at March 31, 2017, versus $125.5 million at the end of 2016 and $136.6 million at March 31, 2016. The Company expects revenue for the second quarter of 2017 to range from $170 million to $175 million, with the expected sequential decline primarily attributable to seasonal decreases and client attrition in the lower gross margin Western Canada pipeline inspection business that is part of the North America Staffing vertical.  In contrast, the Company expects revenue to be largely stable sequentially across its other business verticals.  The Company also expects the impact of revenue pressure in the second quarter to be substantially offset by improvement in gross margin as a result of favorable changes in service mix to higher margin solutions verticals, and by lower operating expenses. At 4:30 p.m. Eastern Time on May 10, 2017, Michael S. Castleman, President and Interim CEO, will host a webcast to discuss the first quarter 2017 results and business outlook. The webcast can be accessed live, via the Internet, at www.cdicorp.com. CDI Corp. (NYSE: CDI) seeks to create extraordinary outcomes with our clients by delivering solutions based on skilled technical and professional talent. Our business is comprised of four segments: Enterprise Talent, Specialty Talent & Technology Solutions, Engineering Solutions and MRI. We provide engineering and information technology solutions encompassing managed, project and talent services. Our clients are in multiple industries, including energy, chemicals, infrastructure, aerospace, industrial equipment and technology, and also include municipal and state governments and the U.S. Department of Defense. We have offices and delivery centers in the U.S. and Canada. In addition, we provide recruiting and staffing services through our global MRINetwork® of franchisees. Learn more at www.cdicorp.com This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, from time to time, we and our representatives may make statements that are forward-looking. All statements that address expectations or projections about the future, including, but not limited to, statements about our plans, strategies, adequacy of resources and future financial results (such as revenue, gross profit, operating profit, cash flow, and tax rate), are forward-looking statements. Some of the forward-looking statements can be identified by words like "anticipates," "believes," "expects," "may," "will," "could," "should," "intends," "plans," "estimates" and similar references to future periods. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions that are difficult to predict. Because these forward-looking statements are based on estimates and assumptions that are subject to significant business, economic and competitive uncertainties, many of which are beyond our control or are subject to change, actual outcomes and results may differ materially from what is expressed or forecasted in these forward-looking statements. Important factors that could cause actual results to differ materially from these forward-looking statements include, but are not limited to: weakness or volatility in general economic conditions and levels of capital spending by clients in the industries we serve; weakness or volatility in the financial and capital markets, which may result in the postponement or cancellation of our clients' projects or the inability of our clients to pay our fees; the termination of one or more major client contracts or projects; the uncertain timing and funding of new contract awards and renewals; a high concentration of our business with a few large clients; the impact and outcome of our decision to explore strategic alternatives, as announced on March 20, 2017; the failure to achieve the anticipated benefits of acquisitions, and difficulties in integrating acquired businesses with CDI; the inability to obtain favorable price and other terms for any acquisitions and divestitures we may do; delays or reductions in government spending; credit risks associated with our clients; competitive market pressures; foreign currency fluctuations; restrictions on the availability of funds and on our activities under our asset-based, secured credit facility; the availability, retention and cost of qualified labor; our level of success in attracting, training, and retaining qualified management personnel and other staff employees; changes in tax laws and other government regulations, including the impact of health care reform laws and regulations; the possibility of incurring liability for our business activities, including, but not limited to, the activities of our professional employees and our temporary employees; our performance on client contracts; negative outcome of pending and future claims and litigation; improper disclosure or loss of sensitive or confidential company, client, government, employee or candidate information, including personal data; and government policies, legislation or judicial decisions adverse to our businesses. More detailed information about these and other risks and uncertainties may be found in our filings with the United States Securities and Exchange Commission (SEC), particularly in the "Risk Factors" section in Part I, Item 1A of the Company's Annual Report on Form 10-K for the year ended December 31, 2016. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We assume no obligation to update such statements, whether as a result of new information, future events or otherwise, except as required by law. Unless the context otherwise requires, all references herein to "CDI," the "Registrant," the "Company," "we," "us" or "our" are to CDI Corp. and its consolidated subsidiaries. Use of Non-GAAP Financial Measures This press release contains financial information calculated other than pursuant to U.S. Generally Accepted Accounting Principles (GAAP). In particular, it includes Adjusted EBITDA and Adjusted EBITDA Margin which are adjusted to exclude from net loss interest, income taxes, depreciation and amortization expense, restructuring and other related costs, share-based compensation expense, certain corporate development related costs and earnout adjustments, and Adjusted EPS which excludes from diluted earnings per common share certain corporate development related costs, earnout adjustments, amortization of acquired intangibles, and the related income tax effect. We present these as supplemental measures of performance. These non-GAAP measures have limitations as analytical tools, should not be viewed as a substitute for financial information determined in accordance with GAAP, and should not be considered in isolation or as a substitute for analysis of the Company's results as reported under GAAP. Some of the limitations of Adjusted EBITDA and Adjusted EPS as analytical tools are: (i) these measures do not reflect all our cash expenditures, or future requirements, for capital expenditures or contractual commitments; (ii) these measures do not reflect changes in, or cash requirements for, our working capital needs; (iii) these measures do not reflect interest expense, or the cash requirements necessary to service interest or principal payments, on our debts; (iv) although depreciation and amortization are non-cash charges, the assets being depreciated and amortized often will have to be replaced in the future, and Adjusted EBITDA does not reflect any cash requirements for such replacements; (v) share-based compensation is and will remain a key element of our overall long-term incentive compensation package, although we exclude it from Adjusted EBITDA as an expense when evaluating our ongoing operating performance for a particular period; (vi) these measures do not reflect the impact of certain cash charges resulting from matters we consider not to be indicative of our ongoing operations; and (vii) other companies in our industry may calculate these measures differently than we do, limiting its usefulness as a comparative measure. We present these non-GAAP financial measures because we believe these assist investors and analysts in comparing our performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. These non-GAAP financial measures are also used by management in its evaluation of core operations and financial and operational decision-making. Reconciliations of non-GAAP Financial Measures to U.S. GAAP Financial Measures : Summary of Historical Impact of Anders on Reported Results Reconciliations of Supplemental non-GAAP Financial Measures to U.S. GAAP Financial Measures : To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cdi-corp-reports-first-quarter-2017-results-300455501.html


Patent
Cdi Inc. | Date: 2014-03-17

A sealing assembly for sealing an annulus in a downhole application including a sealing ring and a deflecting ring axially aligned between axially opposed mesh back-ups, each of the sealing ring and the deflecting ring defining a first ramped end, the first ramped ends facing each other such that an axial set force applied to the deflecting ring deflects the sealing ring radially outward forcing the sealing ring into a side-by-side arrangement with the deflecting ring to fill and seal the annulus.


A flowmeter of the thermal type, having a heated flow-sensing element and a temperature-sensing reference element, the elements constructed and arranged to be installed in a pressurized pipe. The flowmeter has one probe with the heated element and a separate second probe with the reference element. The probes are constructed and arranged to pass through the pipe wall in separate through-holes. There is a mounting structure such as a split ring that is adapted to be mounted to the pipe. Two valves operatively coupled to separate locations of the mounting structure, where one probe passes through each valve and into the pipe.


Patent
Cdi Inc. | Date: 2016-04-19

A flowmeter of the thermal type, having a heated flow-sensing probe and a temperature-sensing reference probe, in which the flow is passed through nozzles to form two jets and those jets are directed at the heated portion of the heated probe and the temperature-sensing portion of the reference probe, while flow around the supporting portion of the heated probe is minimized. Such a flowmeter allows low gas flows to be measured without the use of capillary elements that are subject to plugging and can create unwanted pressure drops.


A flowmeter of the thermal type, having a heated flow-sensing element and a temperature-sensing reference element, the elements constructed and arranged to be installed in a pressurized pipe. The flowmeter has one probe with the heated element and a separate second probe with the reference element. The probes are constructed and arranged to pass through the pipe wall in separate through-holes. There is a mounting structure such as a split ring that is adapted to be mounted to the pipe. Two valves operatively coupled to separate locations of the mounting structure, where one probe passes through each valve and into the pipe.


Patent
Cdi Inc. | Date: 2015-01-23

A piston pump including a cylinder body having an internal fluid chamber, a piston configured to axially cycle within the cylinder body, an inlet valve, an outlet valve, an annular seal positioned between the piston and cylinder body, a barrier fluid pocket formed in the cylinder body adjacent one end of the annular seal, and a barrier fluid contained within the barrier fluid pocket, the barrier fluid preventing suspended solids in pumped fluid from contacting the annular seal.

Loading Cdi Inc. collaborators
Loading Cdi Inc. collaborators